Before We Start
Same drug class, two different jobs
Calcium channel blockers block calcium influx into smooth muscle and cardiac cells, but the two subtypes have meaningfully different clinical uses. Dihydropyridines act mostly on vascular smooth muscle — they're vasodilators, first-line for hypertension. Non-dihydropyridines (verapamil, diltiazem) act on the heart itself, slowing AV nodal conduction and heart rate, so they're used for atrial fibrillation/rate control and certain arrhythmias too.
💡 The Suffix Shortcut
Almost every dihydropyridine ends in "-dipine" (amlodipine, nifedipine, felodipine) — that suffix alone tells you it's a vasodilator, not a rate-control drug. Verapamil and diltiazem are the two non-dihydropyridines worth memorizing by name since they don't follow that pattern.
Side Effects by Type
What to watch for in each family
Dihydropyridines — Edema and Reflex Tachycardia
Peripheral vasodilation has predictable downstream effects
Because these drugs relax peripheral vessels, patients commonly develop dependent peripheral edema (ankles/feet) — this isn't fluid overload and doesn't respond to diuretics the way heart failure edema does. Rapid vasodilation can also trigger reflex tachycardia as the body compensates for the drop in vascular resistance.
Non-Dihydropyridines — Bradycardia Risk
Contraindicated in patients who are already slow
Verapamil and diltiazem slow the heart directly, so they're avoided in patients with bradycardia, sick sinus syndrome, or existing AV block — combining them with a beta blocker (which also slows the heart) requires particular caution. Verapamil is also well known for causing significant constipation.
💊 "If a CCB order doesn't fit a patient with a slow heart rate, it's the non-dihydropyridine that's the problem — dihydropyridines don't carry that risk."
🏥 Clinical Scenario
A patient with a history of atrial fibrillation and a heart rate of 48 bpm is newly prescribed a calcium channel blocker.
Nurse Action
The nurse checks which CCB was ordered before administering. If it's verapamil or diltiazem, the nurse holds the dose and contacts the provider — a rate-slowing CCB in a patient already bradycardic could worsen the bradycardia significantly. A dihydropyridine like amlodipine would not carry the same immediate concern.
📌 NCLEX Application
NCLEX pairs the two CCB subtypes against each other constantly:
Identify by suffix: "Which of these is a dihydropyridine calcium channel blocker?" → Any drug ending in "-dipine."
Contraindication: "A calcium channel blocker is contraindicated in a patient with 2nd-degree heart block. Which drug is this most likely referring to?" → Verapamil or diltiazem (non-dihydropyridines).
Side effect differentiation: "A patient on amlodipine develops new ankle swelling. What is the priority nursing action?" → Recognize this as an expected vasodilation-related side effect, not necessarily fluid overload, and report per protocol rather than reflexively giving a diuretic.
⚠️ The Trap — Treating All CCBs the Same
Assuming every calcium channel blocker carries the same bradycardia risk (or the same edema profile) leads to missed contraindications and unnecessary alarm. The safeguard: always identify which CCB subtype is in play before predicting its side-effect profile — the "-dipine" suffix is the fastest way to sort them.
✓ Quick Self-Test
1. What suffix identifies most dihydropyridine CCBs?
2. Which two CCBs are non-dihydropyridines, and what extra risk do they carry?
3. What side effect is classically associated with verapamil specifically?
Answers:
1. "-dipine" (amlodipine, nifedipine, felodipine).
2. Verapamil and diltiazem — they slow heart rate/AV conduction and are contraindicated in bradycardia or heart block.
3. Constipation.
Next Lesson
ACE Inhibitors
→